MX348611B - Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana. - Google Patents

Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.

Info

Publication number
MX348611B
MX348611B MX2012007735A MX2012007735A MX348611B MX 348611 B MX348611 B MX 348611B MX 2012007735 A MX2012007735 A MX 2012007735A MX 2012007735 A MX2012007735 A MX 2012007735A MX 348611 B MX348611 B MX 348611B
Authority
MX
Mexico
Prior art keywords
compositions
treatment
inflammatory bowel
bowel disease
prophylaxis
Prior art date
Application number
MX2012007735A
Other languages
English (en)
Other versions
MX2012007735A (es
Inventor
Milton Trachtman Ira
Original Assignee
Milton Trachtman Ira
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milton Trachtman Ira filed Critical Milton Trachtman Ira
Publication of MX2012007735A publication Critical patent/MX2012007735A/es
Publication of MX348611B publication Critical patent/MX348611B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a infección bacteriana, en donde dicha forma de dosificación comprende: (i) un componente de liberación retardada comprendiendo una cantidad de antibiótico efectiva para reducir la colonización de bacterias patogénicas en el tracto gastrointestinal, comprendiendo dicho antibiótico una combinación de sulfametoxazol, y trimetoprim; y (ii) un componente de liberación inmediata que comprende una formulación de probióticos en una cantidad efectiva para restaurar las colonias de microflora normal en el intestino, en donde dicho componente de liberación inmediata libera dicha formulación de probióticos luego del contacto con el fluido en el estómago; y en donde dicho componente de liberación retardada libera dicho antibiótico a un pH de 7 o mayor.
MX2012007735A 2009-12-31 2010-12-29 Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana. MX348611B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29147409P 2009-12-31 2009-12-31
PCT/US2010/062339 WO2011082218A1 (en) 2009-12-31 2010-12-29 Compositions and method for treatment and prophylaxis of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
MX2012007735A MX2012007735A (es) 2012-09-28
MX348611B true MX348611B (es) 2017-06-21

Family

ID=44226799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007735A MX348611B (es) 2009-12-31 2010-12-29 Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.

Country Status (7)

Country Link
US (4) US9138441B2 (es)
EP (1) EP2519108A4 (es)
AU (1) AU2010339573B2 (es)
CA (1) CA2785658C (es)
IL (1) IL220613B (es)
MX (1) MX348611B (es)
WO (1) WO2011082218A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
WO2012012146A2 (en) * 2010-06-30 2012-01-26 The Regents Of The University Of Colorado Compositions and methods to modulate progression and onset of inflammatory bowel disease
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
CN103082292B (zh) * 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
WO2014011233A1 (en) * 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
SE1251123A1 (sv) * 2012-10-05 2014-04-06 Indevex Ab Publ Födoämnesprodukt
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
DK3628161T3 (da) 2012-11-23 2023-05-30 Seres Therapeutics Inc Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2014212004B2 (en) 2013-02-04 2018-09-20 Société des Produits Nestlé S.A. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
US20160206564A1 (en) * 2013-09-27 2016-07-21 Ira Milton Trachtman Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
KR102611070B1 (ko) 2013-11-25 2023-12-07 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10799541B2 (en) 2014-07-01 2020-10-13 Probi USA, Inc. Bi-layer dual release probiotic tablets
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
KR20180030459A (ko) * 2015-03-09 2018-03-23 바이오이뮤나이저 에스에이지엘 항산화제와 비피도박테리아 및 프로바이오틱스로부터 분리된 세포벽이 조합된 조합물을 포함하는 항-노화 조성물
JP7111700B2 (ja) 2016-09-16 2022-08-02 デュポン ニュートリション バイオサイエンシーズ エーピーエス 細菌
MX2020001774A (es) 2017-08-14 2020-09-09 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedad colestásica.
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
US12163135B2 (en) 2017-12-05 2024-12-10 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN109170163A (zh) * 2018-09-29 2019-01-11 华南农业大学 一种含有纳豆芽孢杆菌的高效饲料添加剂
US11813296B2 (en) * 2018-10-04 2023-11-14 Deerland Enzymes, Inc. Bacillus subtilis probiotics and methods of use for improving immune function, hormonal status, and physical performance
JP2022504792A (ja) * 2018-10-10 2022-01-13 セルバトゥス リミテッド 炎症性疾患及び関連する感染の治療方法
CN114225024B (zh) * 2021-12-29 2022-08-19 山东健袖生态科技有限公司 一种用于治疗疾病的益生菌药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
ATE290391T1 (de) 1998-12-11 2005-03-15 Urex Biotech Inc Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
ES2713954T3 (es) 2004-05-14 2019-05-24 Merck Sharp & Dohme Tratamiento de enfermedades asociadas al uso de antibióticos
EP1931363B1 (en) * 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
WO2007081981A2 (en) * 2006-01-11 2007-07-19 Attune Foods Probiotic food, process for its preparation and dietary regimen
US20070298018A1 (en) * 2006-06-23 2007-12-27 Lacpro Industries, Llc Novel lactobacillus bulgaricus strain and compositions
JP5140154B2 (ja) 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics
RU2010143460A (ru) 2008-05-01 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для терапии восстановительных состояний кишечника
WO2009158384A1 (en) * 2008-06-27 2009-12-30 The Procter & Gamble Company Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders
EP2485742A4 (en) * 2009-10-06 2013-03-20 Scott Dorfner ANTIBIOTIC FORMULATIONS WITH REDUCED SIDE EFFECTS ON STOMACH AND DARM
PE20121185A1 (es) 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.

Also Published As

Publication number Publication date
US20160000839A1 (en) 2016-01-07
CA2785658A1 (en) 2011-07-07
EP2519108A1 (en) 2012-11-07
US9492488B2 (en) 2016-11-15
AU2010339573B2 (en) 2014-08-28
CA2785658C (en) 2017-10-24
EP2519108A4 (en) 2013-10-16
IL220613B (en) 2018-06-28
US9138441B2 (en) 2015-09-22
US20170246226A1 (en) 2017-08-31
WO2011082218A1 (en) 2011-07-07
US9649348B2 (en) 2017-05-16
AU2010339573A1 (en) 2012-07-19
US20170056456A1 (en) 2017-03-02
IL220613A0 (en) 2012-08-30
MX2012007735A (es) 2012-09-28
US20120276201A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
MX348611B (es) Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
WO2014011564A3 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
MY148872A (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
IN2012DN01638A (es)
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
PL2249824T3 (pl) Laktylany w zapobieganiu i leczeniu infekcji wywoływanych bakteriami gram-dodatnimi u zwierząt
HK1218560A1 (zh) 组成与方法
PT2544698T (pt) Composição contendo bactérias probióticas para utilização no tratamento de distúrbios imunitários
MY146595A (en) Probiotic bifidobacterium strains
MY189329A (en) Mixture of non-digestible oligosaccharides for stimulating the immune system
PH12012501540A1 (en) Probiotic composition for use in the treatment of bowel inflammation
MX2011011949A (es) Metodos para el tratamiento de enfermedades mediante el uso de un cambiador epimetabólico (coenzima q10).
WO2012149549A3 (en) Bacillus bacteria for use in treating and preventing infection in aquatic animals
PL3016667T3 (pl) Probiotyczne szczepy bakteryjne do zapobiegania i leczenia chorób w jamie ustnej
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2011005370A (es) Formas de dosis orales de sufentanilo que comprenden agentes barredores de oxígeno y métodos de uso de los mismos.
IL225581B (en) Defibrotide for use in the prevention and/or treatment of graft-versus-host disease (gvhd)
PL2457576T3 (pl) Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji
IL256966A (en) Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
LT2854826T (lt) Lactobacillus reuteri atcc pta 6475, skirtas panaudoti kaulų masės praradimo prevencijai arba gydymui žinduoliuose
HU0700745D0 (en) Use of edta and its derivatives for the prevention and treatment of bacterial intestinal swine diseases and for enhancement of efficiency of antibiotics in curing such ilnesses

Legal Events

Date Code Title Description
FG Grant or registration